Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Benzodiazepine compound topical pharmaceutical composition and preparation method and use

A composition and compound technology, applied in the direction of drug combination, pharmaceutical formula, medical preparations of non-active ingredients, etc., can solve the problems of inconvenient injection of preparations, high cost of industrial production, inconvenient medication for patients, etc., to achieve convenient self-management , Guaranteed drug efficacy, avoiding the effect of hepatic first-pass effect

Active Publication Date: 2022-05-27
YICHANG HUMANWELL PHARMA
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compound (R) shown in formula (I) has been reported in Chinese patent CN103202815B 1 and R 2 Both are freeze-dried preparations of salts of methyl), the preparation cycle of the freeze-drying process is long, about 5 days a production cycle, the amount of excipients is large, the cost of industrial production is high, and the preparation requires professional medical personnel to inject it, which is very inconvenient
[0004] Most of the current literature reports are that the compound shown in formula (I) is prepared as a freeze-dried powder preparation and then used clinically. The preparation process of this dosage form has a long production cycle and high production costs; clinically, it needs to be temporarily formulated into a solution before it can be used clinically. It is used under the guidance of a professional doctor, and it is often accompanied by injection pain during injection, which makes it inconvenient for patients to take medication and has poor compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzodiazepine compound topical pharmaceutical composition and preparation method and use
  • Benzodiazepine compound topical pharmaceutical composition and preparation method and use
  • Benzodiazepine compound topical pharmaceutical composition and preparation method and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Example 1 Compound (R) represented by formula (I) 1 is methyl, R 2 Preparation of transdermal patch for methyl)benzenesulfonate

[0076] (1) Compound (R) represented by formula (I) 1 is methyl, R 2 Be methyl) benzene sulfonate 8g and Soluplus7.4g, magnesium stearate 0.5g micronization, add polyethylene glycol (molecular weight 2000) 14g, mix well, make physical mixture;

[0077] (2) Set the extrusion temperature of the twin-screw extruder to be 120°C, start the screw after rising to the set temperature, add the physical mixture in the step (1) to the extruder, and then heat-melt and extrude, It is extruded into spherical particles to obtain amorphous particles, which are then micronized to obtain micronized amorphous particles, and the particle size is controlled at about 100-150 nm.

[0078] (3) Weigh 3 g of micronized amorphous particles prepared in step (2), 2 g of soybean lecithin, 0.3 g of cholesterol, 30 g of dehydrated alcohol, and 64.7 g of water;

[0079] ...

Embodiment 2

[0086] Embodiment 2 Compound (R) represented by formula (I) 1 is methyl, R 2 Preparation of transdermal patch for ethyl)

[0087] (1) Compound (R) represented by formula (I) 1 is methyl, R 2 For ethyl) 0.9g and povidone (PVP-S630) 3.1g, talc 0.2g micronized, add polyethylene glycol (molecular weight 4000) 5.8g, mix uniformly to obtain a physical mixture;

[0088] (2) Set the extrusion temperature of the twin-screw extruder to be 120°C, start the screw after rising to the set temperature, add the physical mixture in the step (1) to the extruder, and then heat-melt and extrude, It is extruded into spherical particles to obtain amorphous particles, which are then micronized to obtain micronized amorphous particles, and the particle size is controlled at about 150-175 nm.

[0089] (3) Weighing the compound (R) represented by the formula (I) prepared in step (2) 1 is methyl, R 2 ethyl) micronized amorphous particles 0.3g, phosphatidylcholine 2g, cholesterol 0.3g, propylene gl...

Embodiment 3

[0097] Embodiment 3 Compound (R) represented by formula (I) 1 for hydrogen, R 2 Preparation of transdermal patch for methyl)

[0098] (1) Compound (R) represented by formula (I) 1 for hydrogen, R 2 Be methyl) 0.8g and povidone (PVP-K30) 3g, magnesium stearate 0.2g micronize, add polyethylene glycol (molecular weight 6000) 6.0g, mix well, make physical mixture;

[0099] (2) Set the extrusion temperature of the twin-screw extruder to be 120°C, start the screw after rising to the set temperature, add the physical mixture in the step (1) to the extruder, and then heat-melt and extrude, It is extruded into spherical particles to obtain amorphous particles, which are then micronized to obtain micronized amorphous particles, and the particle size is controlled at about 180-230 nm.

[0100] (3) Weighing the compound (R) represented by the formula (I) prepared in step (2) 1 for hydrogen, R 2 For methyl) micronized amorphous particles 7g, phosphatidylethanolamine 2g, cholesterol 0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a benzodiazepine compound topical pharmaceutical composition, which comprises a benzodiazepine compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a polymer dispersion carrier material, a thermal melt protector and optionally The fluxing agent, R in formula (I) 1 and R 2 See the description for the definition of , the topical pharmaceutical composition is for skin external use and transdermal administration; the preparation method of the topical composition includes the benzodiazepine compound, polymer dispersion The agent is micronized, a melting agent is optionally added, and mixed uniformly to obtain a physical mixture, which is then hot-melt extruded and micronized to obtain the benzodiazepine compound particles. Uses of the above pharmaceutical composition are also provided. The pharmaceutical composition can be used for calming the mind, sedation, hypnosis, improving sleep quality, clearing the mind after use, the compound represented by the formula (I) has no residue or accumulation in the body, does not affect the work of the next day, and is full of energy.

Description

technical field [0001] The present invention relates to pharmaceutical preparation technology, more particularly to a kind of benzodiazepine The topical pharmaceutical composition of the compound (namely the compound represented by formula (I)) and the preparation method and use thereof. The pharmaceutical composition can be used for calming the heart, soothing the mind, sedation, hypnosis, and improving sleep quality. Background technique [0002] The compound represented by formula (I) (wherein, R 1 Selected from hydrogen, methyl, ethyl, isopropyl; R 2 For methyl, ethyl) is a new type of benzodiazepine class of compounds, are short-acting sedatives. Clinically, it can be used for procedural sedation, induction and maintenance of general anesthesia, sedation of ICU patients, etc. Short-acting sedatives allow patients to regain consciousness quickly and be discharged from the hospital as soon as possible. In the face of the gradual increase in short-term hospitalizat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/5517A61K9/70A61K9/127A61K47/28A61K47/10A61P25/20A61P17/02
CPCA61K31/5517A61K9/7023A61K9/127A61K47/28A61K47/10A61P25/20A61P17/02
Inventor 田峦鸢刘朋金芬曲龙妹郭建锋吴有斌汪淼吕金良李莉娥符义刚李仕群李杰杜文涛
Owner YICHANG HUMANWELL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com